What Stoke Therapeutics (STOK)'s ADOA Trial Update Means For Shareholders

Simply Wall St.06:35

Stoke Therapeutics recently shared new preclinical and early clinical data for its antisense drug STK-002 in Autosomal Dominant Optic Atrophy at the AAO 2026 meeting, alongside progress in the Phase 1...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676236205?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-18 06:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676236205","market":"sg","top_or_hot":-1,"title":"What Stoke Therapeutics (STOK)'s ADOA Trial Update Means For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>Stoke Therapeutics recently shared new preclinical and early clinical data for its antisense drug STK-002 in Autosomal Dominant Optic Atrophy at the AAO 2026 meeting, alongside progress in the Phase 1...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/what-stoke-therapeutics-stoks-adoa-trial-update-means-for-sh\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Stoke Therapeutics (STOK)'s ADOA Trial Update Means For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Stoke Therapeutics (STOK)'s ADOA Trial Update Means For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-18 06:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/what-stoke-therapeutics-stoks-adoa-trial-update-means-for-sh><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stoke Therapeutics recently shared new preclinical and early clinical data for its antisense drug STK-002 in Autosomal Dominant Optic Atrophy at the AAO 2026 meeting, alongside progress in the Phase 1...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/what-stoke-therapeutics-stoks-adoa-trial-update-means-for-sh\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/what-stoke-therapeutics-stoks-adoa-trial-update-means-for-sh","article_id":"2676236205","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/what-stoke-therapeutics-stoks-adoa-trial-update-means-for-sh","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676236205","pubTimestamp":1792276509,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Stoke Therapeutics recently shared new preclinical and early clinical data for its antisense drug STK-002 in Autosomal Dominant Optic Atrophy at the AAO 2026 meeting, alongside progress in the Phase 1 OSPREY dose-escalation trial.\nThe presentations connected FALCON natural history findings, OPA1 biology and OSPREY readouts, giving investors a clearer view of how STK-002 could fit into Stoke Therapeutics' rare ophthalmology pipeline, where no approved ADOA treatments currently exist.\nWe will...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","STOK":"Stoke Therapeutics, Inc."},"translate_title":"Stoke Therapeutics (STOK) 的 ADOA 试验更新对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":1.5},"content_text":"Stoke Therapeutics recently shared new preclinical and early clinical data for its antisense drug STK-002 in Autosomal Dominant Optic Atrophy at the AAO 2026 meeting, alongside progress in the Phase 1 OSPREY dose-escalation trial. The presentations connected FALCON natural history findings, OPA1 biology and OSPREY readouts, giving investors a clearer view of how STK-002 could fit into Stoke Therapeutics' rare ophthalmology pipeline, where no approved ADOA treatments currently exist. We will now look at how Stoke Therapeutics' investment narrative could be shaped by STK-002's early ADOA data and trial progress.  Scan beyond Stoke Therapeutics and line up other rare disease opportunities with the hand picked 20 high quality undiscovered gems that could sit beside a high-risk pipeline bet such as STOK. AdvertisementStoke Therapeutics Investment Narrative Recap To own Stoke Therapeutics, you need to believe its antisense platform can translate into approved drugs in rare CNS and eye disorders. Zorevunersen in Dravet syndrome still looks like the key value driver, with the long Phase 3 EMPEROR readout and NDA path shaping the near term outlook. The recent STK-002 AAO data expand the story but do not change the central role of EMPEROR and regulatory decisions in Dravet. The biggest operational risk remains clinical or regulatory setbacks that delay or limit zorevunersen or reveal safety constraints as exposure builds. STK-002 progress increases platform breadth but also extends the period of heavy R&D spend while the business is still loss making, so any requirement for extra data or slower enrollment across programs could keep cash burn elevated for longer. The most relevant linked update is Stoke’s October 5 meeting with the FDA on the planned New Drug Application for zorevunersen in Dravet syndrome. That interaction framed how five years of safety and efficacy data, along with EMPEROR’s seizure and Vineland 3 subdomain results, are expected to be packaged and analyzed for U.S. review. For you as an investor, that zorevunersen plan sets the main commercial catalyst and timing reference point, while the AAO 2026 STK-002 data speak to optionality beyond Dravet. Together they highlight an execution challenge for Stoke Therapeutics, which is running an expensive late stage epilepsy program and an early ophthalmology effort at the same time, both with clinical, payer and partner risk attached. Stoke Therapeutics’ current analyst narrative points to US$177.8 million in revenue and US$33.6 million in earnings by 2029. This outlook is built on a forecast 77.0% yearly revenue growth rate and a swing in earnings of roughly US$203 million, from a loss of US$169.8 million today to the projected 2029 profit. Uncover how Stoke Therapeutics' fair value indicates a potential 87% upside to its current price before the market closes that discount. NasdaqGS:STOK 1-Year Stock Price Chart Exploring Other Perspectives One alternate view focuses on payer risk rather than trial outcomes. The most cautious analysts worry that tight reimbursement for zorevunersen could slow Stoke Therapeutics’ earnings ramp. Before the AAO news, this group was using revenue of about US$23.1 million and earnings of roughly US$4.4 million by 2029, which leaves room for sentiment to shift as new data arrive. Explore 3 other Stoke Therapeutics fair value estimates, including one that suggests it could be worth just $35.00! Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Stoke Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for Stoke Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.  Looking For More Investment Ideas Beyond Stoke Therapeutics? Once you have a handle on Stoke Therapeutics and its risk reward profile, it often helps to line it up against very different types of opportunities so you can balance high conviction views with diversification.  For investors who prefer financially resilient businesses that can help anchor a portfolio, review our list of solid balance sheet and fundamentals (25 results) and see which assets might provide that foundation. If your priority is cushioning volatility with income, scan through the 8 dividend fortresses and see which payers could complement a higher risk biotech position. For those looking for mispriced opportunities with stronger fundamentals, compare Stoke Therapeutics against the 33 high quality undervalued stocks and see where the market may be leaving room for potential benefits.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676236205","isCrawlerRequest":true}